Seqens Seqens

X
[{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion gets approval to add new sites to Phase II trial of SENS-401","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical"},{"orgOrder":0,"company":"Sensorion","sponsor":"Axplora","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sensorion","sponsor":"Cochlear Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sensorion","sponsor":"Association for Research in Otolaryngology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present Three Posters on SENS-401 in Cisplatin Ototoxicity Modelsat the Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Update on SENS-401","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe Conferences in October 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval to Initiate Amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in The UK","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sensorion","sponsor":"Institut Pasteur","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensorion Announces Partnership with the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders has been Extended for Five Years","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$54.4 million","upfrontCash":"Undisclosed","newsHeadline":"Sensorion Announces a \u20ac50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1\/2 Clinical Trial in some European Countries","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"Sensorion Announces a \u20ac15 Million Financing, Extending Cash Runway Until the End of 2025","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by Sensorion

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The financing aims to fund the clinical development of SENS-501 (OTOF-GT) small molecule programs for the treatment and prevention of hearing loss disorders.

            Lead Product(s): OTOF-GT

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Redmile Group

            Deal Size: $16.2 million Upfront Cash: Undisclosed

            Deal Type: Financing April 08, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.

            Lead Product(s): R-Azasetron Besylate

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 11, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through financing, Sensorion will prioritize the development of SENS-501 ( OTOF-GT), which aims to restore hearing in individuals with Otoferlin deficiency, a prevalent form of congenital deafness.

            Lead Product(s): OTOF-GT

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Redmile Group

            Deal Size: $54.4 million Upfront Cash: Undisclosed

            Deal Type: Financing February 09, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.

            Lead Product(s): R-Azasetron Besylate

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 01, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SENS-501 (OTOF-GT) dual vector AAV gene therapy development program aims to restore hearing in patients with mutations in the gene coding for otoferlin protein who suffer from severe to profound sensorineural prelingual non-syndromic hearing loss.

            Lead Product(s): OTOF-GT

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 19, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Sensorion and Institut Pasteur will focus on the development of two gene therapy programs, including SENS-501 (OTOF-GT), which targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT, which targets hearing loss related to mutations in GJB2 gene.

            Lead Product(s): SENS-501

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Institut Pasteur

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 05, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SENS-401 (Arazasetron) is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule, which is under phase 2 clinical development for the treatment of Cisplatin-Induced Ototoxicity (CIO).

            Lead Product(s): R-Azasetron Besylate

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.

            Lead Product(s): SENS-501

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.

            Lead Product(s): OTOF-GT

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SENS-501 is an adeno-associated vector-based gene therapy for the autosomal recessive non-syndromic Deafness 9. It is being investigated in preclinical stage for DFNB9.

            Lead Product(s): SENS-501

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY